{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-25-001555","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.368086+00:00","generated_at":"2026-05-16T22:31:48.741630+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Arcturus Therapeutics Reports Q3 2025 Net Loss of $13.5M, Progresses ARCT-032 and ARCT-810 Programs","bullets":["Q3 2025 revenue was $17.2M, down $24.5M from prior year; net loss $13.5M ($0.49 per share) vs $6.9M loss in Q3 2024.","ARCT-032 Phase 2 interim data: inhaled 10mg daily over 28 days well tolerated; mucus burden reduced in 4 of 6 Class I CF adults per HRCT scans.","Company plans a 12-week safety and efficacy study of ARCT-032 in up to 20 CF participants starting H1 2026.","FDA changes delayed U.S. BLA filing for KOSTAIVE indefinitely; additional cost reductions planned in Q4 2025 to extend cash runway into 2028.","ARCT-2304 pandemic flu vaccine candidate induced humoral immune response after single dose at all tested levels, supporting further development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-25-001555","json":"https://secwatch.observer/filing/0001193805-25-001555.json","markdown":"https://secwatch.observer/filing/0001193805-25-001555.md","text":"https://secwatch.observer/filing/0001193805-25-001555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380525001555/0001193805-25-001555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380525001555/e664953_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T22:31:48.741630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}